美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Portfolio Building Block World Pharma and Biotech Index ETF

28.11

-0.1075-0.38%

盤後：28.130.0228+0.08%19:30 EDT

成交量：6.85萬

成交額：192.13萬

市值：10.21億

市盈率：- -

高：28.16

開：28.16

低：27.98

收：28.21

52周最高：29.90

52周最低：24.24

股本：3,631.00萬

流通股本：3,631.00萬

量比：0.76

換手率：0.19%

股息：0.02

股息率：0.08%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。

118款生物藥專利懸崖將至，中國藥企業迎戰MNC最大專利懸崖

市場消息：派拉蒙天空之舞採取措施防範延期產生的成本，華納兄弟探索併購交易即將完成。

2026年國家醫保談判在北京啓動；珍視明回應滴眼液抽檢不合格事件 | 醫藥早參

每日经济新闻

「很緊張，汗都出來了！」直擊2025年國家醫保談判首日：中藥企業打頭陣

2026年國家醫保談判開啓！早8點代表入場，多家中藥企業亮相

摩根大通投行聯席負責人：併購交易業務有望迎來創紀錄年份。

美股異動丨諾華製藥升逾7%，多發性硬化症口服藥後期臨床試驗結果積極

機構：爭奪天然氣資產推高併購交易規模創2013年以來新高

羅兵咸永道：上半年中國併購交易量7316宗創歷史新高預計下半年延續強勁勢頭

GLP-1為王、專利懸崖逼近、新賽道搶跑跨國藥企2026上半年業績背後的版圖重組

每日经济新闻

GLP-1為王、專利懸崖逼近、新賽道搶跑：跨國藥企2026上半年業績背後的版圖重組

每日经济新闻

畢馬威：併購交易恢復活力年內或迎來分拆浪潮

阿斯利康擬與百時美施貴寶4000億美元重組傳聞背後：專利懸崖、產品短板倒逼，AZ端反對聲大

市場消息：派拉蒙與華納兄弟達成一致，將併購交易暫緩至 2007 年 6 月 1 日。

市場消息：美國司法部將恢復併購交易的「二次信息調取」調查流程。

黑石集團：短期內非人工智能企業相關併購交易將趨於冷清。

數據研究機構Datasite：數據顯示2026上半年全球併購啓動項目數量按年上升31%，併購交易熱度持續升温。

印度仿製藥巨頭盯上國產「替尼」，恒瑞們準備好了嗎？

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/PBPH/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PBPH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBPH\",,,,,undefined,":{"symbol":"PBPH","market":"US","secType":"STK","nameCN":"Portfolio Building Block World Pharma and Biotech Index ETF","latestPrice":28.1072,"timestamp":1789502400000,"preClose":28.2147,"halted":0,"volume":68466,"hourTrading":{"tag":"盘后","latestPrice":28.13,"preClose":28.1072,"latestTime":"19:30 EDT","volume":7,"amount":196.7288,"timestamp":1789515005515,"change":0.0228,"changeRate":0.000811,"amplitude":0},"delay":0,"changeRate":-0.003810070636937543,"floatShares":36310000,"shares":36310000,"eps":0,"marketStatus":"未開盤","change":-0.1075,"latestTime":"09-15 16:00:00 EDT","open":28.16,"high":28.16,"low":27.98,"amount":1921258.042806,"amplitude":0.00638,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789545600000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":28.2147,"nav":28.156506,"aum":1022362732.86,"dividendRate":0.000814,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":28.13,"preClose":28.1072,"latestTime":"19:30 EDT","volume":7,"amount":196.7288,"timestamp":1789515005515,"change":0.0228,"changeRate":0.000811,"amplitude":0},"volumeRatio":0.755224},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBPH\",,,,,undefined,":{"symbol":"PBPH","floatShares":36310000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.755224,"shares":36310000,"dividePrice":0.022885,"high":28.16,"amplitude":0.00638,"preClose":28.2147,"low":27.98,"week52Low":24.241,"pbRate":"--","week52High":29.9,"institutionHeld":0,"latestPrice":28.1072,"eps":0,"divideRate":0.000814,"volume":68466,"delay":0,"ttmEps":0,"open":28.16,"prevYearClose":25.2428,"prevWeekClose":27.8041,"prevMonthClose":28.6563,"prevQuarterClose":27.177,"fiveDayClose":28.152,"twentyDayClose":27.9294,"sixtyDayClose":25.2512},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PBPH\",params:#limit:5,,,undefined,":[{"date":"2025-12-24","symbol":"PBPH","amount":0.022885,"announcedDate":"2025-12-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-24","defaultRemindTime":1766586600000,"name":"Portfolio Building Block World Pharma and Biotech Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-24","currency":"USD","dateTimestamp":1766552400000,"payDate":"2025-12-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PBPH\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-24","recordDate":"2025-12-24","paymentDate":"2025-12-26","value":0.022885,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PBPH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PBPH\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666571008","title":"阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571008?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:23","pubTimestamp":1789158183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["FBT","HELX","IDNA","RXL","LU2272731600.USD","AZNH","BME","IEHS","BK4585","LU2473716301.USD","IEIH","PPH","LU2272731782.SGD","XBIX","LU2322448791.USD","SYNB","LU2322448957.HKD","LU1992135472.HKD","PJP","MRNY","LU2272731865.HKD","MEDI","IBRN","RSPH","PBE","TMED","GNOM","PBPH","BBP","IBB","BBH","CANC","BK4588","BIB","XPH","BIOY","FTXH","MRNX","IE00B5TLWC47.USD","SBIO","LFSC","PSCH","LU1992135399.USD","WDNA","IYH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666563124","title":"118款生物藥專利懸崖將至，中國藥企業迎戰MNC最大專利懸崖","url":"https://stock-news.laohu8.com/highlight/detail?id=2666563124","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666563124?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 15:26","pubTimestamp":1789025185,"startTime":"0","endTime":"0","summary":"BCG合伙人杜菁博士指出，未来几年全球MNC将迎来史上最大专利悬崖，有118种生物制剂将会失去相应的专利保护，涉及2340亿美元市场。然而，目前这118款即将到期分子中，只有极少数在火热开发，大量缺口有待生物类似药填补。目前来说，创新药出海还没办法完成这个闭环，但生物类似药作为先头部队做出海试验，企业风险和获益会更高。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789025064363150858","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["GSKH","FHLC","JDOC","PJP","RSPH","TMED","BBP","159839","APXH","MEDI","IYH","PPH","BME","PBPH","BBH","FXH","IHE","TRUH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666370679","title":"市場消息：派拉蒙天空之舞採取措施防範延期產生的成本，華納兄弟探索併購交易即將完成。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666370679","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666370679?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 05:12","pubTimestamp":1788901933,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PRVT","XLFI","IEFN","VXF","IBBQ","RSPH","BK4108","BK4588","MNA","RFG","BK4585","WMG","UYG","PSP","IYH","CANC","PEVC","TBXU","DFMC","GTPE","FFSM","BK4561","MMID","AAUM","ACTV","PBPH","TMED","BK4571"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665367071","title":"2026年國家醫保談判在北京啓動；珍視明回應滴眼液抽檢不合格事件 | 醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2665367071","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665367071?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 07:01","pubTimestamp":1788735712,"startTime":"0","endTime":"0","summary":"丨2026年9月7日星期一丨NO.12026年国家医保谈判在北京启动9月5日，2026年国家医保目录谈判竞价和商保创新药目录价格协商在北京启动，预计持续4至5天。新版目录有望于11月底前公布，2027年1月1日起执行。与往年相比，今年国谈整体提前约一个月，已有59个创新药完成参考药预沟通，并新增创新药“预申报”。点评：预沟通与预申报缩短创新药准入周期，有利于药企加快商业化节奏。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609073866183218.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609073866183218.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["PBPH","BMED","BK1574","XLVI","09939","APXH","159938","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665636842","title":"「很緊張，汗都出來了！」直擊2025年國家醫保談判首日：中藥企業打頭陣","url":"https://stock-news.laohu8.com/highlight/detail?id=2665636842","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665636842?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 16:59","pubTimestamp":1788598790,"startTime":"0","endTime":"0","summary":"9月5日早上8时，2026年国家基本医保药品目录谈判竞价及商保创新药目录价格协商工作在北京市西城区全国人大会议中心启动，时代周报记者前往现场了解情况。谈判开始之前，已有数十名药企代表在全国人大会议中心门口等候。8时左右，国家医保局工作人员在会议中心门口点名药企代表进入，8:08左右所有参加上午场谈判的药企代表完成入场。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609053866015465.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609053866015465.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["APXH","PBPH","BMED","XLVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665712357","title":"2026年國家醫保談判開啓！早8點代表入場，多家中藥企業亮相","url":"https://stock-news.laohu8.com/highlight/detail?id=2665712357","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665712357?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 09:47","pubTimestamp":1788572828,"startTime":"0","endTime":"0","summary":"本文来源：时代周报2026年国家基本医保药品目录谈判竞价及商保创新药目录价格协商工作，于9月5日早8点在北京市西城区全国人大会议中心启动。时代周报记者从现场了解到，早8点左右，国家医保局工作人员开始在会议中心门口点名药企代表进入；8:08左右所有参加上午场谈判的药企代表完成入场。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609053865981910.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609053865981910.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["XLVI","BMED","APXH","PBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664463098","title":"摩根大通投行聯席負責人：併購交易業務有望迎來創紀錄年份。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664463098","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664463098?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 02:58","pubTimestamp":1788375516,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["AAUM","PBPH","PRVT","DFMC","PSP","GTPE","XLFI","TBXU","IEFN","PGF","RSPH","IBBQ","BK4588","TMED","ACTV","MMID","MNA","BK4585","IYH","RFG","CANC","BK4582","UYG","FFSM","VXF","PEVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664521258","title":"美股異動丨諾華製藥升逾7%，多發性硬化症口服藥後期臨床試驗結果積極","url":"https://stock-news.laohu8.com/highlight/detail?id=2664521258","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664521258?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 22:18","pubTimestamp":1788272338,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LFSC","IE00B4R5TH58.HKD","LU2322448957.HKD","IE00BJJMRZ35.SGD","BIB","MEDX","BK4588","XPH","IDNA","IE0002141913.USD","RSPH","RXL","PBPH","IBRN","BBP","IE00BJT1NW94.SGD","MRNX","FBT","XBIX","BIOY","BK4585","SBIO","AZNH","PJP","MEDI","TMED","IE00BFTCPJ56.SGD","LU0211331839.USD","HELX","IEIH","FTXH","IBB","LU0070302665.USD","MRNY","IE0009355771.USD","PBE","BK4007","PPH","IEHS","BBH","SYNB","WDNA","CANC","NVS","PSCH","LU2473716301.USD","LU2272731600.USD","BME","IYH","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663017770","title":"機構：爭奪天然氣資產推高併購交易規模創2013年以來新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2663017770","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663017770?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 22:52","pubTimestamp":1788187964,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["AAUM","ACTV","IEO","FFSM","TMED","FTXN","GUSH","DBC","BK4585","IYH","VXF","PSP","DUG","BOIL","GTPE","MNA","FCG","CANC","RSPH","ERX","PEVC","IEFN","DRIP","USE","DIG","PXJ","RFG","UYG","BK4588","KOLD","XLFI","DFMC","BK4570","XES","IBBQ","DBE","PBPH","PXE","MMID","IXC","DRLL","XOP","PRVT","WTIU","VDE","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662784028","title":"羅兵咸永道：上半年中國併購交易量7316宗創歷史新高 預計下半年延續強勁勢頭","url":"https://stock-news.laohu8.com/highlight/detail?id=2662784028","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662784028?lang=zh_tw&edition=fundamental","pubTime":"2026-08-25 16:00","pubTimestamp":1787644859,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，普华永道指出，今年上半年，中国并购交易数量达7316宗，同比增加近30%，创下历史新高；交易总额同比增长56%至2416亿美元，为2023年以来最佳半年度表现。普华永道交易服务税务主管合伙人梅梁表示，预期中国并购市场在2026年下半年将延续强劲势头，全年交易总额有望实现同比增长。港交所仅上半年即录得51宗具私募股权背景的IPO，创下同期历史新高，超过半数为高科技企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484962.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IEFN","PEVC","TMED","TBXU","FFSM","AAUM","RSPH","BK4585","PRVT","MMID","DFMC","BK4588","IYH","CANC","GTPE","VXF","RFG","IBBQ","XLFI","UYG","MNA","PSP","ACTV","PBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658535936","title":"GLP-1為王、專利懸崖逼近、新賽道搶跑 跨國藥企2026上半年業績背後的版圖重組","url":"https://stock-news.laohu8.com/highlight/detail?id=2658535936","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658535936?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 20:00","pubTimestamp":1786363243,"startTime":"0","endTime":"0","summary":"近日，全球制药巨头相继交出上半年成绩单。礼来、诺和诺德、赛诺菲、阿斯利康、辉瑞、罗氏等头部企业业绩陆续揭晓。GLP-1赛道的王座之争已无悬念，而专利悬崖、集采冲击与管线焦虑，正迫使跨国药企加速寻找下一个增长引擎。GLP-1王座之争：礼来登顶8月5日，礼来公布2026年上半年业绩——总营收427.73亿美元，同比增长49%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608103836820982.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608103836820982.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["TRUH","JDOC","APXH","BME","IHE","FXH","PPH","GLP","TMED","BBP","MEDI","GSKH","BBH","BK4590","IYH","FHLC","PBPH","RSPH","PJP","BK4144"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657641919","title":"GLP-1為王、專利懸崖逼近、新賽道搶跑：跨國藥企2026上半年業績背後的版圖重組","url":"https://stock-news.laohu8.com/highlight/detail?id=2657641919","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657641919?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 21:49","pubTimestamp":1786110543,"startTime":"0","endTime":"0","summary":"近日，全球制药巨头相继交出上半年成绩单。礼来、诺和诺德、赛诺菲、阿斯利康、辉瑞、罗氏等头部企业业绩陆续揭晓。GLP-1赛道的王座之争已无悬念，而专利悬崖、集采冲击与管线焦虑，正迫使跨国药企加速寻找下一个增长引擎。GLP-1王座之争：礼来登顶8月5日，礼来公布2026年上半年业绩——总营收427.73亿美元，同比增长49%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608073835488463.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608073835488463.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["TRUH","IYH","BK4144","MEDI","FHLC","JDOC","IHE","GSKH","PBPH","APXH","GLP","BBP","PPH","BME","FXH","PJP","BBH","TMED","RSPH","BK4590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657632843","title":"畢馬威：併購交易恢復活力 年內或迎來分拆浪潮","url":"https://stock-news.laohu8.com/highlight/detail?id=2657632843","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657632843?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 21:18","pubTimestamp":1786022287,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MNA","UYG","AAUM","PBPH","CANC","DFMC","IYH","FFSM","IBBQ","PRVT","XLFI","PSP","TBXU","RSPH","IEFN","PEVC","ACTV","BK4588","MMID","RFG","VXF","BK4585","GTPE","TMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656080539","title":"阿斯利康擬與百時美施貴寶4000億美元重組傳聞背後：專利懸崖、產品短板倒逼，AZ端反對聲大","url":"https://stock-news.laohu8.com/highlight/detail?id=2656080539","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656080539?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 17:26","pubTimestamp":1785835565,"startTime":"0","endTime":"0","summary":"蓝鲸新闻记者联系了阿斯利康方面，对方拒绝对此置评。此外，BMS有神经管线与Eliquis后续心血管资产，可补足AZ在相关领域的短板。据BMO资本在研报中指出，两家公司都没有足够的财务实力直接收购对方，预计阿斯利康能掏出约370亿美元，而百时美施贵宝约为320亿美元，远低于搞定一桩价值4000亿美元合并所需的资金。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1785835141389493693","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4588","LU0267386448.USD","BBH","PJP","LU1032466523.USD","MEDI","JDOC","BBP","LU1670710588.SGD","LU1868836591.USD","LU2596442595.SGD","LU0128525929.USD","LU2237443382.USD","LU0432979614.USD","LU2089984988.USD","LU1585245621.USD","LU0321505439.SGD","LU2237443895.HKD","BK4559","LU2462157665.USD","TRUH","LU1868837300.USD","LU1093756168.USD","LU1670711123.USD","LU0321505868.SGD","RSPH","LU0868494617.USD","TMED","IE00B2B36J28.USD","APXH","FTXH","LU2242646821.SGD","AZNH","AZN","LU0225284248.USD","LU1868836914.USD","FXH","BMY","LU0882574055.USD","PPH","IE00BJJMRZ35.SGD","IYH","LU0985481810.HKD","BME","GSKH","AZ","FHLC","LU1093756325.SGD","IHE","PBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654503461","title":"市場消息：派拉蒙與華納兄弟達成一致，將併購交易暫緩至 2007 年 6 月 1 日。","url":"https://stock-news.laohu8.com/highlight/detail?id=2654503461","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654503461?lang=zh_tw&edition=fundamental","pubTime":"2026-07-25 03:34","pubTimestamp":1784921685,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4571","BK4588","IYH","PRVT","AAUM","FFSM","MNA","TMED","UYG","ACTV","BK4561","BK4108","RSPH","PEVC","IBBQ","DFMC","TBXU","VXF","WMG","PSP","RFG","MMID","GTPE","IEFN","XLFI","CANC","PBPH","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653726128","title":"市場消息： 美國司法部將恢復併購交易的 「二次信息調取」 調查流程。","url":"https://stock-news.laohu8.com/highlight/detail?id=2653726128","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653726128?lang=zh_tw&edition=fundamental","pubTime":"2026-07-23 22:21","pubTimestamp":1784816467,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PBPH","IBBQ","ACTV","UYG","MNA","BK4588","RSPH","CANC","BK4585","VXF","FFSM","TBXU","PSP","MMID","RFG","DFMC","GTPE","PEVC","IYH","PRVT","TMED","XLFI","AAUM","IEFN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653728536","title":"黑石集團： 短期內非人工智能企業相關併購交易將趨於冷清。","url":"https://stock-news.laohu8.com/highlight/detail?id=2653728536","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653728536?lang=zh_tw&edition=fundamental","pubTime":"2026-07-23 20:44","pubTimestamp":1784810659,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CPNQ","AAUM","BX","IEFN","TARK","TECY","AIQU","QQA","PEVC","VUSE","OGIG","MFIG","AGIX","AQGX","PBPH","NEWZ","PSP","AIBU","WPAI","PRVT","TBXU","TMED","FFSM","PBOT","ARTY","QSWN","MNA","QID","DQJN","ACTV","UYG","NBDS","CHAT","CANC","GTPE","DFMC","FWD","CWC","VXF","MVPS","IYH","QTOC","LCLG","RSPH","RFG","GK","MMID","KOMP","AIFD","XLFI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653744105","title":"數據研究機構Datasite：數據顯示2026上半年全球併購啓動項目數量按年上升31%，併購交易熱度持續升温。","url":"https://stock-news.laohu8.com/highlight/detail?id=2653744105","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653744105?lang=zh_tw&edition=fundamental","pubTime":"2026-07-23 19:15","pubTimestamp":1784805342,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MNA","UYG","AAUM","PBPH","CANC","DFMC","IYH","PEX","FFSM","IBBQ","PRVT","XLFI","PSP","TBXU","RSPH","IEFN","PEVC","ACTV","BK4588","EVNT","MMID","WSML","RFG","KNO","VXF","BK4585","GTPE","TMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653715466","title":"印度仿製藥巨頭盯上國產「替尼」，恒瑞們準備好了嗎？","url":"https://stock-news.laohu8.com/highlight/detail?id=2653715466","media":"湾财ND","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653715466?lang=zh_tw&edition=fundamental","pubTime":"2026-07-23 12:35","pubTimestamp":1784781300,"startTime":"0","endTime":"0","summary":"2026年7月10日，国家药监局一纸批件打破沉寂——印度仿制药巨头瑞迪博士实验室（Dr.Reddy's，简称DRL）在华合资公司“昆山龙灯瑞迪”，拿下了贝达药业埃克替尼（凯美纳）的首仿获批。几乎同时，这家以极致成本策略著称的“世界药厂”，启动了正大天晴“安罗替尼”的生物等效性预试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607233818672977.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607233818672977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01276","LU0359201885.HKD","LU0359202008.SGD","LU0359201612.USD","BK1587","BK1588","BK1191","LU2543165471.USD","PBPH","LU1023057109.AUD","APXH","00013"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":19,"code":"91000000","status":"200"}]}}